Kathryn Pugh

Kathryn Pugh

Auto-generated profile, based on publicly available information

Kathryn Pugh

Tumor Targeted Delivery, Oncology R&D, AstraZeneca, London, United Kingdom

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SGStephen J. Gregson
Stephen J. Gregson
KPKathryn Pugh
Kathryn Pugh
NPNeki Patel
Neki Patel
SAShameen Afif-Rider
Shameen Afif-Rider
BVBalakumar Vijayakrishnan
Balakumar Vijayakrishnan
PHPhilip W. Howard
Philip W. Howard
Antibody–drug conjugate (ADC) research has typically focused on the release of highly potent cytotoxic agents to achieve antitumor efficacy. However, recently approved ADCs trastuzumab deruxtecan and sacituzumab govitecan release lower-potency topoisomerase inhibitors. This has prompted interest in ADCs that release lower-potency cytotoxic drugs to potentially enhance therapeutic index and reduce unwanted toxicity. Pyrrolobenzodiazepine (PBD) dimer ADCs have been widely investigated in human clinical trials, which have focused on high-potency PBDs. In this study, we evaluated five ADCs that release the low-potency PBD dimer SG3650. The relatively low clogD for this agent facilitated higher drug-to-antibody ratio (DAR) conjugation without the need for antibody engineering or functionalization of the drug. The rank order of potency for DAR 2 site-specific ADCs (conjugated at the C239i position) matched the order for the corresponding free drugs in vitro. Despite free drug SG3650 being inactive in vivo, the DAR 2 ADCs derived from the corresponding drug-linker SG3584 showed antitumor efficacy in solid (anti-HER2) and hematologic (anti-CD22) xenograft models. Antitumor activity could be enhanced by conjugating SG3584 to trastuzumab at higher DARs of 4 and 8 and by adjusting dosing and schedule. Higher-DAR conjugates were stable and displayed good rat pharmacokinetic profiles as measured by ELISA and LC/MS-MS. A single intravenous dose of isotype control SG3584 DAR 2 ADC resulted in no mortality in rats or monkeys at doses of up to 25 and 30 mg/kg, respectively. These findings suggest that further investigations of low-potency PBD dimers in ADCs that target hematologic and solid tumors are warranted.

2 December 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
ATArnaud C. Tiberghien
Arnaud C. Tiberghien
BVBalakumar Vijayakrishnan
Balakumar Vijayakrishnan
AEArman Esfandiari
Arman Esfandiari
MAMahammad Ahmed
Mahammad Ahmed
RPRaul Pardo
Raul Pardo
PHPhilip W. Howard
Philip W. Howard
Antibody–drug conjugates (ADC) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers are currently being evaluated in clinical trials, with encouraging results in Hodgkin and non–Hodgkin lymphomas. The first example of an ADC delivering a PBD DNA cross-linker (loncastuximab tesirine) has been recently approved by the FDA for the treatment of relapsed and refractory diffuse large B-cell lymphoma. There has also been considerable interest in mono-alkylating PBD analogs. We conducted a head-to-head comparison of a conventional PBD bis-imine and a novel PBD mono-imine. Key Mitsunobu chemistry allowed clean and convenient access to the mono-imine class. Extensive DNA-binding studies revealed that the mono-imine mediated a type of DNA interaction that is described as “pseudo cross-linking,” as well as alkylation. The PBD mono-imine ADC demonstrated robust antitumor activity in mice bearing human tumor xenografts at doses 3-fold higher than those that were efficacious for the PBD bis-imine ADC. A single-dose toxicology study in rats demonstrated that the MTD of the PBD mono-alkylator ADC was approximately 3-fold higher than that of the ADC bearing a bis-imine payload, suggesting a comparable therapeutic index for this molecule. However, although both ADCs caused myelosuppression, renal toxicity was observed only for the bis-imine, indicating possible differences in toxicologic profiles that could influence tolerability and therapeutic index. These data show that mono-amine PBDs have physicochemical and pharmacotoxicologic properties distinct from their cross-linking analogs and support their potential utility as a novel class of ADC payload.

15 October 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
Purpose: Folate receptor α (FRα) is expressed in most ovarian cancers. However, only patients with high expression levels are eligible for Elahere, an FRα-targeted microtubule inhibitor antibody–drug conjugate (ADC). Efficacy limitations and safety concerns underscore the need to develop next-generation FRα-targeted ADC to treat tumors expressing variable levels of FRα and incorporate different payloads to reduce safety risks. Herein, we present the characterization of AZD5335, a novel FRα-targeted topoisomerase-1 inhibitor ADC. Experimental Design: The efficacy of AZD5335 was assessed and correlated with FRα expression using cell- and patient-derived models. Focusing on models with low FRα, AZD5335 was directly compared with an Elahere analogue. Additionally, AZD5335 was evaluated in a model of acquired Elahere resistance. Combined treatments, including AZD5335 plus either standard-of-care drugs or a PARP1 inhibitor, were also explored. Results: A single dose of AZD5335 (2.5 mg/kg) achieved an overall response rate of 82% in patient-derived ovarian cancer xenografts (n = 17). Antitumor responses were observed in models expressing both high and low levels of FRα. Specifically within FRα-low models, AZD5335 demonstrated superiority over an Elahere analogue. In the context of acquired Elahere resistance, AZD5335 treatments resulted in complete tumor regressions. Additionally, combining AZD5335 with standard-of-care drugs or a PARP1 inhibitor resulted in enhanced efficacy and sustained durability. Two clinical case studies that demonstrated significant AZD5335 responses in tumors exhibiting high and low FRα expression are also provided. Conclusions: AZD5335 is a promising next-generation ADC capable of targeting ovarian cancers with both high and low FRα expression. AZD5335 demonstrates efficacy in overcoming Elahere resistance and supports combined treatment strategies.

15 December 2025
Verified
Other
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
INT-019 HTRF Specificity and Cross-Reactivity Assay

15 December 2025
Verified
Other
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
AZD5335 Statistical Analyses [Figure 3]

15 December 2025
Verified
Other
Open access
JZJason J. Zoeller
Jason J. Zoeller
RTRavinder Tammali
Ravinder Tammali
RDRoger B. Dodd
Roger B. Dodd
NPNeki V. Patel
Neki V. Patel
AAAlma Andoni
Alma Andoni
PSPuja Sapra
Puja Sapra
AZD5335 Statistical Analyses [Figure 1]